42 related articles for article (PubMed ID: 19786981)
1. Expression and prognostic role of syndecan-2 in prostate cancer.
Popović A; Demirović A; Spajić B; Stimac G; Kruslin B; Tomas D
Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):78-82. PubMed ID: 19786981
[TBL] [Abstract][Full Text] [Related]
2. Methylation of CpG island promoters at
Iwaizumi M; Taniguchi T; Kurachi K; Osawa S; Sugimoto K; Baba S; Sugimura H; Maekawa M
Oncol Lett; 2023 Jan; 25(1):14. PubMed ID: 36478906
[TBL] [Abstract][Full Text] [Related]
3. Eltrombopag binds SDC4 directly and enhances MAPK signaling and macropinocytosis in cancer cells.
Cui C; Pan Y; Zhang C; Zhu D; Xuan Y; Hao P; Ke X; Zhou X; Qu Y
Am J Cancer Res; 2022; 12(6):2697-2710. PubMed ID: 35812066
[TBL] [Abstract][Full Text] [Related]
4. Syndecan Family Gene and Protein Expression and Their Prognostic Values for Prostate Cancer.
Santos NJ; Barquilha CN; Barbosa IC; Macedo RT; Lima FO; Justulin LA; Barbosa GO; Carvalho HF; Felisbino SL
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445387
[TBL] [Abstract][Full Text] [Related]
5. Prognostic signatures associated with high infiltration of Tregs in bone metastatic prostate cancer.
Meng F; Han X; Min Z; He X; Zhu S
Aging (Albany NY); 2021 Jul; 13(13):17442-17461. PubMed ID: 34229299
[TBL] [Abstract][Full Text] [Related]
6. Progressive and Prognostic Performance of an Extracellular Matrix-Receptor Interaction Signature in Gastric Cancer.
Yang X; Chen L; Mao Y; Hu Z; He M
Dis Markers; 2020; 2020():8816070. PubMed ID: 33178362
[TBL] [Abstract][Full Text] [Related]
7. Proteoglycans in the Pathogenesis of Hormone-Dependent Cancers: Mediators and Effectors.
Tzanakakis G; Giatagana EM; Kuskov A; Berdiaki A; Tsatsakis AM; Neagu M; Nikitovic D
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32847060
[TBL] [Abstract][Full Text] [Related]
8. Lung Adenocarcinoma Syndecan-2 Potentiates Cell Invasiveness.
Tsoyi K; Osorio JC; Chu SG; Fernandez IE; De Frias SP; Sholl L; Cui Y; Tellez CS; Siegfried JM; Belinsky SA; Perrella MA; El-Chemaly S; Rosas IO
Am J Respir Cell Mol Biol; 2019 Jun; 60(6):659-666. PubMed ID: 30562054
[TBL] [Abstract][Full Text] [Related]
9. Prospective Evaluation of Chondroitin Sulfate, Heparan Sulfate and Hyaluronic Acid in Prostate Cancer.
da Silva MNR; Mendes A; Martins JRM; Tobias-Machado M; Pinhal MADS
Int Braz J Urol; 2018; 44(6):1139-1146. PubMed ID: 30516927
[TBL] [Abstract][Full Text] [Related]
10. Integrin α2β1 decelerates proliferation, but promotes survival and invasion of prostate cancer cells.
Ojalill M; Parikainen M; Rappu P; Aalto E; Jokinen J; Virtanen N; Siljamäki E; Heino J
Oncotarget; 2018 Aug; 9(65):32435-32447. PubMed ID: 30197754
[TBL] [Abstract][Full Text] [Related]
11. Heparan Sulfate and Heparan Sulfate Proteoglycans in Cancer Initiation and Progression.
Nagarajan A; Malvi P; Wajapeyee N
Front Endocrinol (Lausanne); 2018; 9():483. PubMed ID: 30197623
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer cells specifically reorganize epithelial cell-fibroblast communication through proteoglycan and junction pathways.
Suhovskih AV; Kashuba VI; Klein G; Grigorieva EV
Cell Adh Migr; 2017 Jan; 11(1):39-53. PubMed ID: 27111714
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer stroma: an important factor in cancer growth and progression.
Krušlin B; Ulamec M; Tomas D
Bosn J Basic Med Sci; 2015 May; 15(2):1-8. PubMed ID: 26042506
[TBL] [Abstract][Full Text] [Related]
14. Proteoglycan-based diversification of disease outcome in head and neck cancer patients identifies NG2/CSPG4 and syndecan-2 as unique relapse and overall survival predicting factors.
Farnedi A; Rossi S; Bertani N; Gulli M; Silini EM; Mucignat MT; Poli T; Sesenna E; Lanfranco D; Montebugnoli L; Leonardi E; Marchetti C; Cocchi R; Ambrosini-Spaltro A; Foschini MP; Perris R
BMC Cancer; 2015 May; 15():352. PubMed ID: 25935541
[TBL] [Abstract][Full Text] [Related]
15. Heparan sulfate signaling in cancer.
Knelson EH; Nee JC; Blobe GC
Trends Biochem Sci; 2014 Jun; 39(6):277-88. PubMed ID: 24755488
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine tumors show altered expression of chondroitin sulfate, glypican 1, glypican 5, and syndecan 2 depending on their differentiation grade.
García-Suárez O; García B; Fernández-Vega I; Astudillo A; Quirós LM
Front Oncol; 2014; 4():15. PubMed ID: 24570896
[TBL] [Abstract][Full Text] [Related]
17. Syndecans as modulators and potential pharmacological targets in cancer progression.
Barbouri D; Afratis N; Gialeli C; Vynios DH; Theocharis AD; Karamanos NK
Front Oncol; 2014; 4():4. PubMed ID: 24551591
[TBL] [Abstract][Full Text] [Related]
18. Increased SNAIL expression and low syndecan levels are associated with high Gleason grade in prostate cancer.
Poblete CE; Fulla J; Gallardo M; Muñoz V; Castellón EA; Gallegos I; Contreras HR
Int J Oncol; 2014 Mar; 44(3):647-54. PubMed ID: 24424718
[TBL] [Abstract][Full Text] [Related]
19. RKIP and HMGA2 regulate breast tumor survival and metastasis through lysyl oxidase and syndecan-2.
Sun M; Gomes S; Chen P; Frankenberger CA; Sankarasharma D; Chung CH; Chada KK; Rosner MR
Oncogene; 2014 Jul; 33(27):3528-37. PubMed ID: 23975428
[TBL] [Abstract][Full Text] [Related]
20. Syndecan-2 exerts antifibrotic effects by promoting caveolin-1-mediated transforming growth factor-β receptor I internalization and inhibiting transforming growth factor-β1 signaling.
Shi Y; Gochuico BR; Yu G; Tang X; Osorio JC; Fernandez IE; Risquez CF; Patel AS; Shi Y; Wathelet MG; Goodwin AJ; Haspel JA; Ryter SW; Billings EM; Kaminski N; Morse D; Rosas IO
Am J Respir Crit Care Med; 2013 Oct; 188(7):831-41. PubMed ID: 23924348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
